Praziquantel pharmacokinetics and side effects in Schistosoma japonicum-infected patients with liver disease.
Praziquantel undergoes extensive first-pass hepatic biotransformation, but there is little information on its disposition or toxicity when administered to patients with liver disease. To define the influence of liver disease on the pharmacokinetics of praziquantel, we administered it orally to 30 patients with proven Schistosoma japonicum infection whose liver disease was carefully assessed as being severe, moderate, or absent. Both the peak plasma concentration of praziquantel and the bioava...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date: